Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of N-acetylcysteine on pulmonary hypertension markers in heart failure
IRCT20260224068939N1Phase 2Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of acetylcysteine in pulmonary hypertension due to left heart disease (PH-LHD) and heart failure (HF), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Change in pulmonary artery pressure (PAP), Change in C-reactive protein (CRP) and 2 more. Started Feb 2026; status: completed.
02
Drugs
acetylcysteine
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)heart failure (HF)
Beyond the preview
Go deeper on IRCT20260224068939N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260224068939N1.